BRPI0607523A2 - compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos - Google Patents
compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentosInfo
- Publication number
- BRPI0607523A2 BRPI0607523A2 BRPI0607523-1A BRPI0607523A BRPI0607523A2 BR PI0607523 A2 BRPI0607523 A2 BR PI0607523A2 BR PI0607523 A BRPI0607523 A BR PI0607523A BR PI0607523 A2 BRPI0607523 A2 BR PI0607523A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- methods
- medicaments
- preparation
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- -1 heteroaryl steroid compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000004891 diazines Chemical class 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 102000056262 human PPIG Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- 230000000269 nucleophilic effect Effects 0.000 abstract 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- DBHSVKZZSWTSTN-UHFFFAOYSA-N tributyl(pyridazin-3-yl)stannane Chemical class CCCC[Sn](CCCC)(CCCC)C1=CC=CN=N1 DBHSVKZZSWTSTN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002348 vinylic group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65739005P | 2005-03-02 | 2005-03-02 | |
| PCT/US2006/007143 WO2006093993A1 (en) | 2005-03-02 | 2006-03-02 | Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607523A2 true BRPI0607523A2 (pt) | 2009-09-08 |
Family
ID=36941503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607523-1A BRPI0607523A2 (pt) | 2005-03-02 | 2006-03-02 | compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875599B2 (enExample) |
| EP (2) | EP2206719B1 (enExample) |
| JP (2) | JP5130453B2 (enExample) |
| KR (1) | KR101380959B1 (enExample) |
| CN (2) | CN103349664A (enExample) |
| AT (1) | ATE482969T1 (enExample) |
| AU (1) | AU2006218711B2 (enExample) |
| BR (1) | BRPI0607523A2 (enExample) |
| CA (1) | CA2599953C (enExample) |
| DE (1) | DE602006017175D1 (enExample) |
| DK (2) | DK2206719T3 (enExample) |
| EA (1) | EA019560B1 (enExample) |
| ES (2) | ES2528055T3 (enExample) |
| IL (3) | IL185608A (enExample) |
| MX (1) | MX2007010593A (enExample) |
| NZ (1) | NZ561571A (enExample) |
| PL (2) | PL1853619T3 (enExample) |
| PT (2) | PT1853619E (enExample) |
| SI (2) | SI2206719T1 (enExample) |
| WO (1) | WO2006093993A1 (enExample) |
| ZA (1) | ZA200708106B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| JP5130453B2 (ja) * | 2005-03-02 | 2013-01-30 | ユニバーシティ オブ メリーランド，ボルティモア | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| GB2470873A (en) * | 2008-03-12 | 2010-12-08 | Univ Maryland | Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer |
| US20100048524A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2009120565A2 (en) * | 2008-03-25 | 2009-10-01 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| WO2009129208A2 (en) * | 2008-04-14 | 2009-10-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress reponse |
| EP2334686B1 (en) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
| BRPI0920681A2 (pt) * | 2008-10-28 | 2015-12-29 | Biomarin Pharm Inc | inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17 |
| EP2393827B1 (en) * | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| GB2479693B (en) * | 2009-02-05 | 2014-04-09 | Tokai Pharmaceuticals Inc | Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia |
| WO2010091299A2 (en) * | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel combination cancer therapies |
| PE20121048A1 (es) | 2009-06-26 | 2012-08-25 | Novartis Ag | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 |
| EP2461814A4 (en) * | 2009-08-07 | 2012-12-05 | Tokai Pharmaceuticals Inc | PROSTATE CANCER TREATMENT |
| AU2010319697B2 (en) * | 2009-11-13 | 2016-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
| WO2011066582A1 (en) * | 2009-11-30 | 2011-06-03 | Harbor Biosciences, Inc. | Anticancer compounds and screening method |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| BR112013017635A2 (pt) * | 2010-12-16 | 2016-10-11 | Biomarin Pharm Inc | inibidores de cyp11b, cyp17 e/ou cyp21 |
| MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
| JP2014523445A (ja) * | 2011-07-18 | 2014-09-11 | トーカイ ファーマシューティカルズ，インク． | 前立腺癌を処置するための新規な組成物及び方法 |
| AU2012358219A1 (en) * | 2011-12-22 | 2014-07-10 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using P13K/mTOR inhibitors |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| WO2014165815A2 (en) * | 2013-04-04 | 2014-10-09 | University Of Maryland, Baltimore | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
| KR20160058774A (ko) * | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| SG11201605178WA (en) | 2013-12-24 | 2016-07-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
| CN103694299A (zh) * | 2014-01-13 | 2014-04-02 | 中国药科大学 | 甾体类雄激素受体抑制剂、其制备方法及其医药用途 |
| WO2016119742A1 (zh) * | 2015-01-29 | 2016-08-04 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法 |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2017066697A1 (en) | 2015-10-14 | 2017-04-20 | Dou Qingping | Treatments and diagnostics for cancers |
| IT201600121375A1 (it) * | 2016-11-30 | 2018-05-30 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| ES2700901B2 (es) * | 2016-08-08 | 2019-08-06 | Ind Chimica Srl | Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno. |
| IT201600083406A1 (it) * | 2016-08-08 | 2018-02-08 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| AU2019222651B2 (en) * | 2018-02-13 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase inhibitors and methods of use |
| EP3752517B1 (en) * | 2018-02-13 | 2025-04-09 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase degraders and methods of use |
| AU2020393896A1 (en) | 2019-11-26 | 2022-06-23 | Dana-Farber Cancer Institute, Inc. | Potent and selective azaindole inhibitors of CDK8 and CDK19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA27440A (en) | 1887-08-16 | James T. Walsh | Art of making sheet metal cans, for packing meats, fruits, vegetables, etc. | |
| CH621803A5 (enExample) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
| US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5994335A (en) | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
| PT1660115E (pt) | 2003-07-29 | 2011-08-24 | Dompe Spa | ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE |
| JP5130453B2 (ja) | 2005-03-02 | 2013-01-30 | ユニバーシティ オブ メリーランド，ボルティモア | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
-
2006
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja not_active Expired - Lifetime
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es not_active Expired - Lifetime
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 CA CA2599953A patent/CA2599953C/en not_active Expired - Lifetime
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de not_active Expired - Lifetime
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en not_active Expired - Lifetime
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en not_active Expired - Lifetime
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es not_active Expired - Lifetime
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en not_active Expired
-
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
-
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
-
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2206719T3 (pl) | Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien | |
| EA017278B9 (ru) | Соединения азаиндазола и способы применения | |
| TW200621762A (en) | Novel compounds | |
| NO20076319L (no) | Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav | |
| WO2007087548A3 (en) | Chemical compounds | |
| MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
| AU2003242544A1 (en) | New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents | |
| TW200637874A (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
| WO2007065808A3 (en) | Neuropeptide-2 receptor-agonists | |
| SE0400346D0 (sv) | Steroids for cancer treatment | |
| WO2006096444A3 (en) | Chemical compounds | |
| WO2007054257A3 (en) | Indene derivatives, their preparation and use as medicaments | |
| WO2007073303A3 (en) | Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors | |
| TW200639156A (en) | New compounds | |
| WO2005103010A3 (en) | Pyrazole derivatives useful for the treatment of cancer | |
| SE0401763D0 (sv) | Compounds | |
| IL188848A (en) | A transient receptor antagonist (TRPVI) i, a pharmaceutical preparation containing it for the treatment of related diseases and conditions. | |
| WO2008004100A3 (en) | Therapeutic compounds | |
| WO2003082867A8 (en) | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | |
| CY1115910T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE | |
| UA90039C2 (en) | Neuropeptide-2 receptor-agonists | |
| CR8736A (es) | D-homo-17-cloro-16(17)eno esteroides | |
| BRPI0216272B8 (pt) | derivados do ácido mevalônico, agente antitumoral, composição farmacêutica, e, uso de um derivado do ácido mevalônico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: UNIVERSITY OF MARYLAND (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |